These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39479859)

  • 1. [Research Progress on Prognostic Factors in Patients with Lower-Risk Myelodysplastic Syndrome--Review].
    Liu JN; Chen BA; Cheng J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Oct; 32(5):1626-1630. PubMed ID: 39479859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Jain AG; Ball S; Aguirre L; Al Ali N; Kaldas D; Tinsley-Vance S; Kuykendall A; Chan O; Sweet K; Lancet JE; Padron E; Sallman DA; Komrokji R
    Haematologica; 2024 Jul; 109(7):2157-2164. PubMed ID: 38299605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raising the bar for lower-risk myelodysplastic syndromes.
    Venugopal S; Sekeres MA
    Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When to use which molecular prognostic scoring system in the management of patients with MDS?
    Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The search for better prognostic models in myelodysplastic syndromes.
    Santos FP; Kantarjian H; Garcia-Manero G; Ravandi F
    Curr Hematol Malig Rep; 2011 Mar; 6(1):13-21. PubMed ID: 21136214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of patients with lower-risk myelodysplastic syndromes.
    Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
    Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [GUIDELINES FOR DIAGNOSIS AND TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME].
    Šimec NG; Kaić G; Škrtić A; Šiftar Z; Lasan-Trčić R; Valković T; Puškarić BJ; Rogulj IM; Zatezalo V; Nemet D; Kolonić SO
    Lijec Vjesn; 2017; 139(1-2):1-11. PubMed ID: 30148578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.
    Montalban-Bravo G; Garcia-Manero G
    Am J Hematol; 2018 Jan; 93(1):129-147. PubMed ID: 29214694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current treatment strategies for myelodysplastic syndromes].
    Suzuki T
    Rinsho Ketsueki; 2015 Oct; 56(10):1985-95. PubMed ID: 26458437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C; Giagounidis A; Germing U; Ganser A
    Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lower risk MDS patient at risk of rapid progression.
    Mittelman M; Oster HS; Hoffman M; Neumann D
    Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
    Kewan T; Stahl M; Bewersdorf JP; Zeidan AM
    Curr Hematol Malig Rep; 2024 Jun; 19(3):138-150. PubMed ID: 38632155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2012 Jul; 87(7):692-701. PubMed ID: 22696212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.